Although the combined use of BRAF and MEK inhibition has clearly become a new standard for inhibiting the RAF/MEK/ERK pathway in patients with advanced BRAF mutant melanoma the problem of acquired resistance has become a major stumbling block to obtaining long-term disease control. Here, BRAF is linked to melanoma.